NTRA

SEC source: 0001415889-25-001831 · form4-01212025_090101.xml · derivative · entry 3

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,348 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

F3 · derivative.exercise_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vests upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

F3 · derivative.expiration_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vests upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

SEC source: 0001415889-25-001831 · form4-01212025_090101.xml · nonDerivative · entry 2

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,929

F2 · shares: On January 27, 2023, the Reporting Person was granted a performance-based RSU award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 39,730 shares of Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001831 · form4-01212025_090101.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001836 · form4-01212025_090113.xml · derivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,043 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

F3 · derivative.exercise_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vest upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

F3 · derivative.expiration_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vest upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

SEC source: 0001415889-25-001836 · form4-01212025_090113.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,381

F2 · shares: On January 27, 2023, the Reporting Person was granted a performance-based RSU award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 4,966 shares of Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001836 · form4-01212025_090113.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001835 · form4-01212025_090110.xml · derivative · entry 3

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,696 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

F3 · derivative.exercise_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vests upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

F3 · derivative.expiration_date: On January 28, 2022, the Reporting Person was granted a performance-based RSU award which vests upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

SEC source: 0001415889-25-001835 · form4-01212025_090110.xml · nonDerivative · entry 2

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,332

F2 · shares: On January 27, 2023, the Reporting Person was granted a performance-based RSU award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 24,832 shares of Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001835 · form4-01212025_090110.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001344 · form4-01102025_090101.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 199,804

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.00 to $175.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 44,782

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.33 to $160.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 45,070

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.32 to $160.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 45,802

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.30 to $159.04 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 44,782

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.42 to $160.96 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 45,086

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.32 to $160.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 45,641

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.30 to $159.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,372

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.29 to $161.02 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,942

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.27 to $160.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-000683 · form4-01032025_090101.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255,842

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.24 to $159.20 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030118 · form4-12232024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,706

F1 · shares: Represents a charitable contribution by the Reporting Person.

SEC source: 0001415889-24-030183 · form4-12262024_091204.xml · nonDerivative · entry 3

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,142

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on October 22, 2021.

SEC source: 0001415889-24-030183 · form4-12262024_091204.xml · nonDerivative · entry 2

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,810

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on October 22, 2021.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,997

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,420

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,423

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030183 · form4-12262024_091204.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,811

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On December 20, 2024, the criteria was satisfied for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock..

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,425

F3 · shares: On August 30, 2024, the Reporting Person was granted RSUs covering 3,044 shares of Common Stock which vest upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On December 20, 2024, the criteria was satisfied for the vesting of RSUs covering 3,044 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,381

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On December 20, 2024, the criteria was satisfied for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-24-030118 · form4-12232024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,787

F1 · shares: Represents a charitable contribution by the Reporting Person.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 46,282

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.90 to $168.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 46,778

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.8350 to $167.5900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 47,630

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.7000 to $166.1750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 46,282

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.90 to $168.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 46,585

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.8650 to $167.8200 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 47,544

F5 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.7000 to $166.3450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,072

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.8750 to $168.4350 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,609

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.87 to $167.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-030009 · form4-12202024_091201.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 259,434

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.70 to $166.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029400 · form4-12132024_091202.xml · nonDerivative · entry 5

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,389,180

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.15 to $168.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029400 · form4-12132024_091202.xml · nonDerivative · entry 4

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,394,480

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.00 to $167.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029400 · form4-12132024_091202.xml · nonDerivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,399,407

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.00 to $166.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029400 · form4-12132024_091202.xml · nonDerivative · entry 2

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,445,176

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029400 · form4-12132024_091202.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,520,499

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.00 to $164.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029037 · form4-12112024_091204.xml · nonDerivative · entry 1

Chapman Rowan E · CIK 0001786240 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,202

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.22 to $170.32 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · derivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,323 shares

Expires 2025-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options shares are fully exercisable.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · derivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,752 shares

Expires 2025-03-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options shares are fully exercisable.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,912

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the exercise of options and in compliance with Rule 10b5-1.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.5937 to $166.5938 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,770

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,447

SEC source: 0001415889-24-028605 · form4-12092024_041201.xml · derivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 68,496 shares

Expires 2024-12-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option shares are fully exercisable.